Neurogene (NGNE) Cash from Operations (2013 - 2026)
Neurogene's (NGNE) quarterly Cash from Operations came in at 26100000.0 in Q1 2026, down 25.64% YoY from 35098485.24 in Q1 2025, and down 49.37% on a QoQ basis from 17473000.0 in Q4 2025.
Powered by 
Analysis
Neurogene (NGNE) Cash from Operations (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Cash from Operations data on file, last reported at 26100000.0 in Q1 2026.
- Quarterly Cash from Operations fell 25.64% year-over-year to 26100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 82499000.0 (down 18.32% YoY) and the FY2025 annual result came in at 77173000.0, down 9.31% from the prior year.
- Cash from Operations retreated to 26100000.0 in Q1 2026, from 17473000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9289000.0 in Q3 2022 to a low of 26100000.0 in Q1 2026.
- A 5-year average of 16358705.88 and a median of 16972000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations climbed 17.26% — and 2024, when it sank 70.07%.
- Tracing NGNE's Cash from Operations over 5 years: stood at 18126000.0 in 2022, then increased by 6.37% to 16972000.0 in 2023, then dropped by 3.09% to 17496000.0 in 2024, then gained by 0.13% to 17473000.0 in 2025, then plunged by 49.37% to 26100000.0 in 2026.
- The last three Cash from Operations figures came in at 26100000.0 (Q1 2026), 17473000.0 (Q4 2025), and 19500000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | -23.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.78 Mn |
| Mar 31, 2026 | -26.12 Mn |
| Dec 31, 2025 | -17.46 Mn |
| Sep 30, 2025 | -19.51 Mn |
| Jun 30, 2025 | -19.44 Mn |
| Mar 31, 2025 | -20.80 Mn |
| Dec 31, 2024 | -17.50 Mn |
| Sep 30, 2024 | -15.56 Mn |
| Jun 30, 2024 | -15.84 Mn |
| Mar 31, 2024 | -21.70 Mn |
| Dec 31, 2023 | -16.92 Mn |
| Sep 30, 2023 | -11.60 Mn |
| Jun 30, 2023 | -9.30 Mn |
| Mar 31, 2023 | -13.60 Mn |
| Dec 31, 2022 | -18.15 Mn |
| Sep 30, 2022 | -9.29 Mn |
| Jun 30, 2022 | -11.29 Mn |
| Mar 31, 2022 | -14.09 Mn |
| Dec 31, 2021 | -12.17 Mn |
| Sep 30, 2021 | -8.76 Mn |